Onconetix And Ocuvex Therapeutics Announce Merger Agreement; Onconetix To Acquire All Issued And Outstanding Equity Interest Of Ocuvex, Ocuvex Equity Holders To Receive Onconetix Common Stock Equal To 90% Of Issued And Outstanding Equity Interest In Combined Co.

Author: Benzinga Newsdesk | July 16, 2025 07:20am

Pursuant to the Merger Agreement, Onconetix will acquire all of the issued and outstanding equity interests of Ocuvex and, in consideration for their equity interests, Ocuvex equity holders will receive newly-issued shares of Onconetix common stock equal to 90% of the issued and outstanding equity interests in the combined company as of immediately following the closing of the Proposed Transaction, on a fully diluted basis, subject to adjustment due to any transaction-related equity financing. Onconetix shareholders will retain 10% of the issued and outstanding equity interests in the combined company on a fully diluted basis as of immediately following the Proposed Transaction.

 

Posted In: ONCO